文献速递物质与行为成瘾

伐尼克兰联合医学管理对酒精使用障碍合并吸烟的随机临床试验

Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

这项2期随机双盲安慰剂对照试验纳入131名酒精依赖且频繁暴饮和吸烟的成人,发现伐尼克兰组总体重饮酒日百分比变化与安慰剂无显著差异,但存在显著治疗×性别×时间交互,男性重饮酒减少更多而女性更少;伐尼克兰组持续戒烟率13%显著高于安慰剂组0%。

要点

  • 伐尼克兰1mg每日两次联合医学管理未显著降低总体重饮酒日百分比,但存在显著治疗×性别×时间交互。
  • 男性中伐尼克兰组无重饮酒日比例29%高于安慰剂组6%,女性中伐尼克兰组5%低于安慰剂组25%。
  • 伐尼克兰组持续戒烟率13%,安慰剂组0%,差异显著(P=.003)。

核心结论

  • 伐尼克兰联合医学管理可减少男性重饮酒并提高总体样本的戒烟率。
  • 伐尼克兰可考虑用于改善具有双重行为健康风险的男性。

研究设计与样本

  • 2期随机双盲平行组安慰剂对照试验,2012年9月19日至2015年8月31日在2个门诊诊所进行。
  • 131名符合酒精依赖标准且每周重饮酒≥2次和每周吸烟≥2次的参与者随机分配至伐尼克兰或安慰剂,按性别和站点分层。
  • 干预为伐尼克兰酒石酸盐1mg每日两次或匹配安慰剂片共16周,医学管理强调4周药物依从性后支持改变饮酒。
  • 所有分析为意向性治疗分析。

主要发现

  • 伐尼克兰与安慰剂在跨性别和站点的重饮酒日百分比平均变化无显著差异。
  • 重饮酒日百分比存在显著治疗×性别×时间交互(F1,106=4.66;P=.03),男性伐尼克兰组对数转换重饮酒日百分比下降更大(LS均值差0.54;95%CI -0.09至1.18;P=.09;Cohen d=0.45),女性下降更小(LS均值差-0.69;95%CI -1.63至0.25;P=.15;Cohen d=-0.53)。
  • 男性中伐尼克兰组无重饮酒日比例29%(13/45)高于安慰剂组6%(3/47)(Cohen h=0.64;95%CI 0.22-1.03),女性中伐尼克兰组5%(1/19)低于安慰剂组25%(5/20)(Cohen h=-0.60;95%CI -1.21至0.04)。
  • 伐尼克兰组持续戒烟率13%(8/64),安慰剂组0%(0/67)(P=.003;Cohen h=0.72;95%CI 0.38-1.07)。

关键数值与推荐

  • 重饮酒定义为男性每次≥5杯、女性每次≥4杯。
  • 主要结局为第9至16周重饮酒日百分比、第9至16周无重饮酒日和第13至16周持续戒烟。

临床怎么用

  • 对酒精使用障碍合并吸烟的男性患者,可考虑使用伐尼克兰联合医学管理以减少重饮酒并促进戒烟。
  • 女性患者使用伐尼克兰减少重饮酒的效果可能较差,需个体化评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Individuals with alcohol use disorder have high rates of cigarette smoking. Varenicline tartrate, an approved treatment for smoking cessation, may reduce both drinking and smoking. OBJECTIVES: To test the efficacy of varenicline with medical management for patients with alcohol use disorder and comorbid smoking seeking alcohol treatment, and to evaluate the secondary effects on smoking abstinence. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, double-blind, parallel group, placebo-controlled trial was conducted at 2 outpatient clinics from September 19, 2012, to August 31, 2015. Eligible participants met alcohol-dependence criteria and reported heavy drinking (≥5 drinks for men and ≥4 drinks for women) 2 or more times per week and smoking 2 or more times per week; 131 participants were randomized to either varenicline or placebo stratified by sex and site. All analyses were of the intention-to-treat type. Data analysis was conducted from February 5, 2016, to September 29, 2017. INTERVENTIONS: Varenicline tartrate, 1 mg twice daily, and matching placebo pills for 16 weeks. Medical management emphasized medication adherence for 4 weeks followed by support for changing drinking. MAIN OUTCOMES AND MEASURES: Percentage of heavy drinking days (PHDD) weeks 9 to 16, no heavy drinking days (NHDD) weeks 9 to 16, and prolonged smoking abstinence weeks 13 to 16. RESULTS: Of 131 participants, 39 (29.8%) were women and 92 (70.2%) were men, the mean (SD) age was 42.7 (11.7) years, and the race/ethnicity self-identified by most respondents was black (69 [52.7%]). Sixty-four participants were randomized to receive varenicline, and 67 to receive placebo. Mean change in PHDD between varenicline and placebo across sex and site was not significantly different. However, a significant treatment by sex by time interaction for PHDD (F1,106 = 4.66; P = .03) revealed that varenicline compared with placebo resulted in a larger decrease in log-transformed PHDD in men (least square [LS] mean difference in change from baseline, 0.54; 95% CI, -0.09 to 1.18; P = .09; Cohen d = 0.45) but a smaller decrease in women (LS mean difference, -0.69; 95% CI, -1.63 to 0.25; P = .15; Cohen d = -0.53). Thirteen of 45 men (29%) had NHDD taking varenicline compared with 3 of 47 men (6%) taking placebo (Cohen h = 0.64; 95% CI, 0.22-1.03), whereas 1 of 19 women (5%) had NHDD compared with 5 of 20 women (25%) taking placebo (Cohen h = -0.60; 95% CI, -1.21 to 0.04). Taking varenicline, 8 of 64 participants (13%) achieved prolonged smoking abstinence; no one (0 of 67) quit smoking taking placebo (P = .003; Cohen h = 0.72; 95% CI, 0.38-1.07). CONCLUSIONS AND RELEVANCE: Varenicline with medical management resulted in decreased heavy drinking among men and increased smoking abstinence in the overall sample. Varenicline could be considered to promote improvements in men with these dual behavioral health risks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01553136.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. O'Malley SS, Zweben A, Fucito LM, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29261824. doi:10.1001/jamapsychiatry.2017.3544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。